Live Breaking News & Updates on Myrisk hereditary cancer test
Stay updated with breaking news from Myrisk hereditary cancer test. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) has been assigned a consensus rating of “Hold” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating on […] ....
Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective boosted by research analysts at The Goldman Sachs Group from $28.00 to $31.00 in a research report issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. The Goldman Sachs Group’s target price would suggest a potential upside of […] ....
Myriad Genetics (NASDAQ:MYGN) Updates FY23 Earnings Guidance kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
Myriad Genetics (NASDAQ:MYGN) Releases FY23 Earnings Guidance themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) shares shot up 2.7% on Thursday . The company traded as high as $18.76 and last traded at $18.73. 139,980 shares were traded during mid-day trading, a decline of 73% from the average session volume of 523,469 shares. The stock had previously closed at $18.24. Wall Street […] ....